The stock of Vir Biotechnology Inc (VIR) has gone up by 40.27% for the week, with a 30.04% rise in the past month and a 43.32% rise in the past quarter. The volatility ratio for the week is 14.27%, and the volatility levels for the past 30 days are 7.08% for VIR. The simple moving average for the last 20 days is 30.18% for VIR stock, with a simple moving average of 20.18% for the last 200 days.
Is It Worth Investing in Vir Biotechnology Inc (NASDAQ: VIR) Right Now?
Company’s 36-month beta value is 0.51.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for VIR is 87.71M, and currently, short sellers hold a 7.47% ratio of that floaft. The average trading volume of VIR on January 14, 2025 was 2.01M shares.
VIR) stock’s latest price update
Vir Biotechnology Inc (NASDAQ: VIR)’s stock price has plunge by -13.06relation to previous closing price of 12.10. Nevertheless, the company has seen a 40.27% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-13 that This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at 27.80% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.20% of loss for the given period.
Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 14.27%, as shares surge +34.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.24% upper at present.
During the last 5 trading sessions, VIR rose by +40.27%, which changed the moving average for the period of 200-days by +5.52% in comparison to the 20-day moving average, which settled at $8.08. In addition, Vir Biotechnology Inc saw 43.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from SATO VICKI L, who sale 10,960 shares at the price of $12.52 back on Jan 08 ’25. After this action, SATO VICKI L now owns 1,312,391 shares of Vir Biotechnology Inc, valued at $137,219 using the latest closing price.
VICKI LEE SATO, the Director of Vir Biotechnology Inc, proposed sale 43,840 shares at $7.89 during a trade that took place back on Jan 08 ’25, which means that VICKI LEE SATO is holding shares at $345,898 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -6.58 for the present operating margin
- 0.82 for the gross margin
The net margin for Vir Biotechnology Inc stands at -6.78. The total capital return value is set at -0.37. Equity return is now at value -36.58, with -30.10 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.14. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -2165.5.
Currently, EBITDA for the company is -664.85 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 16.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.94.
Conclusion
In a nutshell, Vir Biotechnology Inc (VIR) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
